menu

Global Fibromyalgia Treatment Market

Schedule Call

Global Fibromyalgia Treatment Market

Global Fibromyalgia Treatment Market by Drug Class (Antidepressants, Antiepileptics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2022-2030

GR - 437049 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: January 27, 2023

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Global Fibromyalgia Treatment Market Scope

Report Attribute

Details

Market Size Value in 2021

US$ 15.72 billion

Revenue Forecast in 2030

US$ 24.24 billion

CAGR

4.9%

Base Year for Estimation

2021

Forecast Period

2022-2030

Historical Year

2020

Segments Covered

Drug Class, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, and the Rest of the World (RoW)

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global fibromyalgia treatment market was valued at US$ 15.72 billion in 2021 and is expected to register a CAGR of 4.9% to reach US$ 24.24 billion by 2030. 

Fibromyalgia Treatment Market Fundamentals

Fibromyalgia, commonly known as fibromyalgia syndrome, is a persistent neurologic disorder that produces extensive discomfort. The disease has no established cause; nevertheless, it can be caused due to various factors, such as genetic causes, physical or mental damage, or infections. Some of the fibromyalgia symptoms include extensive pain, extreme exhaustion, sleep issues, and cognitive impairments. Even though most of the diagnosed fibromyalgia population receives prescription medication therapy, the majority of present treatments are ineffective. Patients have insufficient pain relief, highlighting the need for improved treatment of fibromyalgia secondary symptoms. A physical examination can help discover discomfort and rule out other causes of muscular pain. This condition has no diagnostic tests, such as X-rays or blood testing.

Fibromyalgia patients should try non-drug therapy in addition to any medications prescribed by their doctors. Studies have shown physical activity to be the most effective therapy for fibromyalgia. Exercise should be done in conjunction with any pharmacological treatment. Regular aerobic activities assist patients the best. Other body-based therapies, such as Tai Chi and yoga, can help to alleviate fibromyalgia symptoms. Some sort of trigger usually causes fibromyalgia. It can be back pain, arthritis, injury, or physical stress. Emotional stress may also precipitate this sickness. As a result, how the body "talks" to the spinal cord and brain changes. The U.S. Food and Drug Administration (FDA) has authorized three medications to treat fibromyalgia.

[553058]

Fibromyalgia Treatment Market Dynamics

The rising number of trauma cases and surgeries is the major factor driving the fibromyalgia treatment market. As fibromyalgia is associated with age, the increase in the geriatric population can eventually result in the revenue growth of the fibromyalgia treatment market. For instance, according to WHO, in 2030, 1 in 6 people worldwide are expected to be aged 60 years or above. The share of the population aged 60 years and over is likely to increase from 1 billion in 2020 to 1.4 billion in 2030. Additionally, rising road accidents are projected to boost revenue growth opportunities in the global market. Moreover, increase in focus of leading players on R&D activities to develop new theories for the treatment of fibromyalgia and rise in the number of product approvals and launches are expected to drive the market revenue growth in the next few years.

However, patent expiration and side effects caused due to drugs are likely to impede the global fibromyalgia treatment market revenue growth during the forecast period. 

Fibromyalgia Treatment Market Ecosystem

The global fibromyalgia treatment market has been analyzed from three perspectives: drug class, distribution channel, and region.

Fibromyalgia Treatment Market by Drug Class

[4242423]

Based on the drug class, the global fibromyalgia treatment market is segmented into antidepressants, antiepileptics, muscle relaxants, and others.

The antiepileptics segment accounted for the largest market revenue share in 2021, owing to the rising usage of antiepileptics in fibromyalgia treatment. While antiepileptics medication, such as pregabalin, is commonly utilized to treat epilepsy, it has also been found to be effective in managing the symptoms of fibromyalgia. Pregabalin has been approved by the FDA as a treatment option for fibromyalgia, as it inhibits the release of certain neurotransmitters that contribute to pain.

The antidepressants segment accounts for the second-largest market revenue share. This drug class can help in treating social anxiety disorder and seasonal affective disorder. To a certain extent, antidepressants are helpful in the treatment of fibromyalgia. Amitriptyline, a tricyclic antidepressant (TCA), is a popular therapy choice. These factors are expected to propel the overall segment growth. 

Fibromyalgia Treatment Market by Distribution Channel

Based on the distribution channel, the global fibromyalgia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

The retail pharmacies segment dominated the market with the largest market share in 2021 owing to the availability of over-the-counter medicines for treating fibromyalgia. Drugs, such as acetaminophen, and NSAIDs, such as aspirin, ibuprofen, and naproxen, are some of the over-the-counter medicines available for treating fibromyalgia. In most cases, fibromyalgia treatment does not require hospitalizations, thus attributing a higher market revenue share to the retail pharmacies segment.

The hospital pharmacies segment accounted for the second-largest market revenue share in 2021. This can be attributed to the availability of well-qualified medical staff in hospitals, which are required for the treatment of severe fibromyalgia.

Fibromyalgia Treatment Market by Region

Based on the region, the global fibromyalgia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America dominated the global fibromyalgia treatment market revenue share in 2021, owing to the presence of advanced technologies, major international companies, a large geriatric population, and the rising prevalence of trauma cases and surgeries. Various research organizations and corporations are increasing R&D activities to produce new therapies and novel medications. For instance, in December 2022, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical firm, confirmed the first 50% of participants in the Phase 3 RESILIENT trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of fibromyalgia had been randomized. An interim review of the first 50% of randomized participants by an Independent Data Monitoring Committee (IDMC) for a potential sample size modification or early discontinuation for futility is scheduled in the second quarter of 2023. 

The market in Asia Pacific is expected to be the fastest-growing region for fibromyalgia therapy, due to an increase in traffic accidents. According to a report by the Government of India Ministry of Road Transport & Highways' Road Accidents in India, about 4,12,432 road accidents were recorded by States and Union Territories during the calendar year 2021, claiming 1,53,972 deaths and injuring 3,84,448 people. The average number of traffic accidents increased by 12.6% in 2021, as compared to the previous year, 2020. 

Fibromyalgia Treatment Market Competitive Landscape

The prominent players operating in the global fibromyalgia treatment market are:

  • Pfizer, Inc. 
  • Novartis AG
  • GlaxoSmithKline plc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • Allergan
  • Intec Pharma Ltd.
  • Innovative Med Concepts
  • Theravance Biopharma
  • Forest Pharmaceuticals, Inc.

Fibromyalgia Treatment Market Strategic Developments

  • In November 2022, Swing Therapeutics presented data that supported the usage of its digital therapeutic to provide behavioral therapy for fibromyalgia management. Swing Therapeutics presented preliminary findings from a prospective single-arm clinical study (REACT-FM) at the American College of Rheumatology (ACR) annual meetings. Swing Therapeutics created Stanza, a prescription smartphone-based digital therapy for fibromyalgia, which was intended to help adult patients manage the psychosocial symptoms of fibromyalgia, such as anxiety, sadness, and insomnia.
  • In November 2022, NeuroMetrix, Inc. presented Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, in Philadelphia, Pennsylvania. Quell Fibromyalgia is a wearable neuromodulation technology that is the first and only FDA-approved medical device to assist in alleviating fibromyalgia symptoms. Quell Fibromyalgia comes from the NeuroMetrix pipeline of prescription wearable neurotherapeutics, two of which achieved FDA Breakthrough Device Designation: fibromyalgia and chemotherapy-induced peripheral neuropathy.
  • In May 2022, Scilex Holding Company, a Biopharmaceutical Company focused on developing non-opioid treatment therapies for patients with acute and chronic pain, announced the safety data from Scilex’s Phase 1 clinical trial of SP-104 for the treatment of fibromyalgia. SP-104 is a unique, patented, fixed dosage, delayed burst release formulation of 4.5 mg naltrexone hydrochloride for treating fibromyalgia. Data from a phase 1 clinical research demonstrated that SP-104 treated healthy volunteers with fewer side effects than immediate-release naltrexone-treated individuals.

Frequently Asked Questions About This Report

The fibromyalgia treatment market is expected to be valued at US$ 24.24 billion in 2030.

The fibromyalgia treatment market is expected to register a revenue CAGR of 4.9% during the forecast period from 2022 to 2030.

Patent expiration and side effects caused due to drugs are some factors restricting the global market revenue growth.

The rising prevalence of trauma cases and surgeries, increasing older population, technological advancements, and continuous R&D activities by research institutes are driving the market revenue growth.

Pfizer, Inc., Novartis AG, GlaxoSmithKline plc., Bayer AG, and Teva Pharmaceutical Industries Ltd are among the prominent players in the global market.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trend (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL FIBROMYALGIA TREATMENT MARKET- ANALYSIS & FORECAST, BY DRUG CLASS
    1. Antidepressants
      1. Duloxetine
      2. Amitriptyline
      3. Others
    2. Antiepileptics
      1. Pregabalin
      2. Others 
    3. Muscle Relaxants
    4. Others
  6. GLOBAL FIBROMYALGIA TREATMENT MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies 
    3. Online Pharmacies 
  7. GLOBAL FIBROMYALGIA TREATMENT MARKET- ANALYSIS & FORECAST, BY REGION
    1. North America Fibromyalgia Treatment Market
      1. North America Fibromyalgia Treatment Market, by Drug Class
      2. North America Fibromyalgia Treatment Market, by Distribution Channel
      3. North America Fibromyalgia Treatment Market, by Country
        1. U.S.
          1. U.S. Fibromyalgia Treatment Market, by Drug Class
          2. U.S. Fibromyalgia Treatment Market, by Distribution Channel
        2. Canada
          1. Canada Fibromyalgia Treatment Market, by Drug Class
          2. Canada Fibromyalgia Treatment Market, by Distribution Channel
    2. Europe Fibromyalgia Treatment Market
      1. Europe Fibromyalgia Treatment Market, by Drug Class
      2. Europe Fibromyalgia Treatment Market, by Distribution Channel
      3. Europe Fibromyalgia Treatment Market, by Country/Region
        1. Germany
          1. Germany Fibromyalgia Treatment Market, by Drug Class
          2. Germany Fibromyalgia Treatment Market, by Distribution Channel
        2. U.K
          1. U.K Fibromyalgia Treatment Market, by Drug Class
          2. U.K Fibromyalgia Treatment Market, by Distribution Channel
        3. France
          1. France Fibromyalgia Treatment Market, by Drug Class
          2. France Fibromyalgia Treatment Market, by Distribution Channel
        4. Spain
          1. Spain Fibromyalgia Treatment Market, by Drug Class
          2. Spain Fibromyalgia Treatment Market, by Distribution Channel
        5. Italy
          1. Italy Fibromyalgia Treatment Market, by Drug Class
          2. Italy Fibromyalgia Treatment Market, by Distribution Channel
        6. Rest of Europe 
          1. Rest of Europe Fibromyalgia Treatment Market, by Drug Class
          2. Rest of Europe Fibromyalgia Treatment Market, by Distribution Channel
    3. Asia Pacific Fibromyalgia Treatment Market
      1. Asia Pacific Fibromyalgia Treatment Market, by Drug Class
      2. Asia Pacific Fibromyalgia Treatment Market, by Distribution Channel
      3. Asia Pacific Fibromyalgia Treatment Market, by Country/Region
        1. China
          1. China Fibromyalgia Treatment Market, by Drug Class
          2. China Fibromyalgia Treatment Market, by Distribution Channel
        2. Japan
          1. Japan Fibromyalgia Treatment Market, by Drug Class
          2. Japan Fibromyalgia Treatment Market, by Distribution Channel
        3. India
          1. India Fibromyalgia Treatment Market, by Drug Class
          2. India Fibromyalgia Treatment Market, by Distribution Channel
        4. South Korea
          1. South Korea Fibromyalgia Treatment Market, by Drug Class
          2. South Korea Fibromyalgia Treatment Market, by Distribution Channel
        5. Australia
          1. Australia Fibromyalgia Treatment Market, by Drug Class
          2. Australia Fibromyalgia Treatment Market, by Distribution Channel
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Fibromyalgia Treatment Market, by Drug Class
          2. Rest of Asia Pacific Fibromyalgia Treatment Market, by Distribution Channel
    4. Rest of the World Fibromyalgia Treatment Market
      1. Rest of the World Fibromyalgia Treatment Market, by Drug Class
      2. Rest of the World Fibromyalgia Treatment Market, by Distribution Channel
      3. Rest of the World Fibromyalgia Treatment Market, by Region
        1. Rest of the World Fibromyalgia Treatment Market, by Drug Class
        2. Rest of the World Fibromyalgia Treatment Market, by Distribution Channel
        3. Latin America
          1. Latin America Fibromyalgia Treatment Market, by Drug Class
          2. Latin America Fibromyalgia Treatment Market, by Distribution Channel
        4. Middle East & Africa
          1. Middle East & Africa Fibromyalgia Treatment Market, by Drug Class
          2. Middle East & Africa Fibromyalgia Treatment Market, by Distribution Channel
  8. COMPANY PROFILES         
    1. Pfizer, Inc. 
      1. Business Snapshot
      2. Products Offered
      3. Financial Details*
      4. Strategic Development
    2. Novartis AG
    3. GlaxoSmithKline plc.
    4. Bayer AG
    5. Teva Pharmaceutical Industries Ltd.
    6. Sanofi
    7. Eli Lilly and Company
    8. AbbVie, Inc.
    9. Johnson & Johnson Services, Inc.
    10. AstraZeneca
    11. Allergan
    12. Intec Pharma Ltd.
    13. Innovative Med Concepts
    14. Theravance Biopharma
    15. Forest Pharmaceuticals, Inc.

*Insights on financial performance are subject to availability of information in the public domain

 

List of Tables

  1. Global Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million)
  2. Global Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  3. Global Fibromyalgia Treatment Market, by Region, 2020-2030 (US$ Million) 
  4. North America Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  5. North America Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million)
  6. North America Fibromyalgia Treatment Market, By Country, 2020-2030 (US$ Million) 
  7. U.S. Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  8. U.S. Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  9. Canada Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  10. Canada Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  11. Europe Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  12. Europe Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  13. Europe Fibromyalgia Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  14. Germany Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  15. Germany Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  16. U.K. Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  17. U.K. Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  18. France Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  19. France Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  20. Italy Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  21. Italy Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  22. Spain Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  23. Spain Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  24. Rest of Europe Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  25. Rest of Europe Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  26. Asia Pacific Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  27. Asia Pacific Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  28. Asia Pacific Fibromyalgia Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  29. China Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  30. China Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  31. Japan Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  32. Japan Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  33. India Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  34. India Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  35. South Korea Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  36. South Korea Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  37. Australia Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  38. Australia Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  39. Rest of Asia Pacific Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  40. Rest of Asia Pacific Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million)
  41. Rest of the World Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  42. Rest of the World Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  43. Rest of the World Fibromyalgia Treatment Market, By Region, 2020-2030 (US$ Million) 
  44. Latin America Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  45. Latin America Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  46. Middle East and Africa Fibromyalgia Treatment Market, By Drug Class, 2020-2030 (US$ Million) 
  47. Middle East and Africa Fibromyalgia Treatment Market, By Distribution Channel, 2020–2030 (US$ Million)

 

List of Figures

  1. Fibromyalgia Treatment Market Ecosystem  
  2. Snapshot of Global Fibromyalgia Treatment Market, 2020-2030 
  3. Snapshot of Global Fibromyalgia Treatment Market, By Region, 2020-2030 
  4. Global Fibromyalgia Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Fibromyalgia Treatment Market: Key Players & Competitive Positioning (2021) 
  6. Fibromyalgia Treatment Market: Market Dynamics 
  7. Global Fibromyalgia Treatment Market for Antidepressants, 2020-2030 (US$ Million) 
  8. Global Antidepressants in Fibromyalgia Treatment Market for Duloxetine, 2020-2030 (US$ Million) 
  9. Global Antidepressants in Fibromyalgia Treatment Market for Amitriptyline, 2020-2030 (US$ Million) 
  10. Global Antidepressants in Fibromyalgia Treatment Market for Others, 2020-2030 (US$ Million) 
  11.  
  12. Global Fibromyalgia Treatment Market for Antiepileptic, 2020-2030 (US$ Million) 
  13. Global Antiepileptic in Fibromyalgia Treatment Market for Pregabalin, 2020-2030 (US$ Million) 
  14. Global Antiepileptic in Fibromyalgia Treatment Market for Others, 2020-2030 (US$ Million) 
  15. Global Fibromyalgia Treatment Market for Muscle Relaxants, 2020-2030 (US$ Million) 
  16. Global Fibromyalgia Treatment Market for Others, 2020-2030 (US$ Million) 
  17. Global Fibromyalgia Treatment Market for Hospital Pharmacy, 2020-2030 (US$ Million) 
  18. Global Fibromyalgia Treatment Market for Retail Pharmacy, 2020-2030 (US$ Million) 
  19. Global Fibromyalgia Treatment Market for Online Pharmacy, 2020-2030 (US$ Million) 
  20.  North America Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  21. U.S. Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  22. Canada Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  23. Europe Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  24. Germany Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  25. U.K. Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  26. France Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  27. Italy Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  28. Spain Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  29. Rest of Europe Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  30. Asia Pacific Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  31. China Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  32. Japan Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  33. India Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  34. South Korea Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  35. Australia Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  36. Rest of Asia Pacific Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  37. Rest of the World Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  38. Latin America Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  39. Middle East & Africa Fibromyalgia Treatment Market, 2020-2030 (US$ Million) 
  40. Pfizer, Inc. Revenue from 2018-2021 (US$ Billion) 
  41. Novartis AG Revenue from 2018-2021 (US$ Billion) 
  42. GlaxoSmithKline plc. Revenue from 2018-2021 (US$ Billion) 
  43. Bayer AG Revenue from 2018-2021 (US$ Billion) 
  44. Teva Pharmaceutical Industries Ltd. Revenue from 2018-2021 (US$ Billion) 
  45. Sanofi Revenue from 2018-2021 (US$ Billion) 
  46. Eli Lilly and Company Revenue from 2018-2021 (US$ Billion) 
  47. AbbVie, Inc. Revenue from 2018-2021 (US$ Billion) 
  48. Johnson & Johnson Services, Inc. Revenue from 2018-2021 (US$ Billion) 
  49. AstraZeneca Revenue from 2018-2021 (US$ Billion) 
  50. Allergan Revenue from 2018-2021 (US$ Billion) 
  51. Intec Pharma Ltd. Revenue from 2018-2021 (US$ Billion) 
  52. Innovative Med Concepts Revenue from 2018-2021 (US$ Billion) 
  53. Theravance Biopharma Revenue from 2018-2021 (US$ Billion) 
  54. Forest Pharmaceuticals, Inc. Revenue from 2018-2021 (US$ Billion) 

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Global Fibromyalgia Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Global Fibromyalgia Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports